Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures.

There were high rates of pretreatment status epilepticus (48%) and treatment-resistant seizures, with 93% receiving ≥ 3 antiseizure medications before lacosamide.

Most received intravenous lacosamide, with a median loading dose of 5.0 mg/kg and median daily dose of 7.3 mg/kg.

Seizure burden, measured in seizure minutes per hour, was lower at both 4 h and 7 days following lacosamide administration.

In addition, there was a median reduction in seizure frequency of 30 seizures per day at 7 and 30 days posttreatment ( p < .05).